Calcineurin inhibitors: 40 years later, can’t live without
The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.
Abstract
Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calcineurin inhibitors, including ciclosporin and tacrolimus, inhibit T cell proliferation and activation through targeting IL-2 (58).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [58]
In the citing paper
“Ciclosporin and tacrolimus are immunosuppressants that inhibit calcineurin, a key signaling phosphatase, by binding to their respective immunophilins - cyclophilin and FKBP12 (76).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
In the citing paper
“A major downstream effect is suppression of interleukin (IL)-2 transcription, thereby inhibiting T cells differentiation, survival, and subsequent antibody production and CTL activities via effector TH cells.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [76]
Citations
Cites
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325 · cited 2×
“Regulatory T cells have been shown to be essential for immune tolerance induction in transplantation (16).”
BackgroundTRANSCRIPTION FACTORS OF THE NFAT FAMILY:Regulation and Function
Rao, A., Luo, C., & Hogan, P. G. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.707 · Cited by 2,603 · cited 1×
“scriptional activation of genes encoding cytokines, including IL-2 and IL-4, and CD40 ligand (12).”
BackgroundThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Creighton, T. E. (1992) · Cited by 1,583
Biological effects of cyclosporin A: A new antilymphocytic agent
Borel, J. F., Feurer, C., Gubler, H. U., & Stähelin, H. (1976) · Agents and Actions · doi:10.1007/bf01973261 · Cited by 1,509 · cited 1×
“Many mechanisms were suggested, including an imbalance between vasoconstrictive and vasodilatory mediators (46), an activation of the renin-angiotensin-aldosterone system (47), an increase in the release of endothelin (5), an increase in free radicals (48), and a sympathetic nerve activation in the native kidneys thro…”
BackgroundPirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Calne, R. Y., Rolles, K., Thiru, S., Mcmaster, P., Craddock, G. N., Aziz, S., White, D. J. G., Evans, D. B., Dunn, D. C., Henderson, R. G., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92440-1 · Cited by 1,083
CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS
Calne, R. Y., Thiru, S., Mcmaster, P., Craddock, G. N., White, D. J. G., Evans, D. B., Dunn, D. C., Pentlow, B. D., & Rolles, K. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91970-0 · Cited by 1,002 · cited 1×
“The nephrotoxicity of cyclosporine, reported by Calne and colleagues in the early human studies, remains a major concern for the medical community today (21).”
BackgroundVincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957 · cited 2×
“The cardiovascular and metabolic profiles were better in belatacept groups compared with patients receiving cyclosporine (70).”
Background
Research works printed but not linked: 1
- Klee, 1988, Calcineurin, Adv. Enzymol. Relat. Areas Mol. Biol., 61, 149
Cited by
Items 201–300 of 337
Effect of Fosfomycin on Cyclosporine Nephrotoxicity
Ortega-Trejo, J. A., Pérez‐Villalva, R., Arreola-Guerra, J. M., Ramírez, V., Sifuentes‐Osornio, J., & Bobadilla, N. A. (2020) · Antibiotics · doi:10.3390/antibiotics9100720 · Cited by 4
“Calcineurin inhibitors (CNIs), such as cyclosporine A and tacrolimus, are very effective and widely used around the world for treating allograft rejection (mainly in kidney or liver transplants) and immune disorders [10,11].”
BackgroundDiltiazem as a cyclosporine A-sparing agent in heart transplantation: Benefits beyond dose reduction
Alyaydin, E., Reinecke, H., Tuleta, I., & Sindermann, J. R. (2022) · Medicine · doi:10.1097/md.0000000000031166 · Cited by 4
“All measures were expressed in ng/mL, and the target dose was based on the recommendations of the Guidelines of the International Society for Heart and Lung Transplantation (ISHLT).[3] As our study was conducted in a retrospective setting, and CsA trough levels were used to monitor the immunosuppressive therapy at our…”
BackgroundMethodLarsen, C. P., Vincenti, F. G., Kou, T. D., Shadur, C. A., Bresnahan, B. A., Jordan, S. C., Woodle, E. S., Goes, N. B., Vella, J. P., Wojciechowski, D., et al. (2024) · Transplantation Direct · doi:10.1097/txd.0000000000001644 · Cited by 4
Juvenile Dermatomyositis and Other Inflammatory Myopathies in Children
Pachman, L. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00042-1 · Cited by 6
Lee, S., Lee, H., Kim, Y. A., Lee, I.-H., Kang, S., Sim, K., Park, C., Choi, K., & Youn, H. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00772-6 · Cited by 5
The Transcription Factor NFATc1 Supports the Rejection of Heterotopic Heart Allografts
Baur, J., Otto, C., Steger, U., Klein‐Hessling, S., Muhammad, K., Pusch, T., Murti, K., Wismer, R., Germer, C., Klein, I., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01338 · Cited by 4
Yalçın, K., Çelen, S., Zhumatayev, S., Daloğlu, H., Pashayev, D., Öztürkmen, S., Uygun, V., Karasu, G., & Yeşilipek, A. (2021) · Clinical Transplantation · doi:10.1111/ctr.14328 · Cited by 4
Dome, P. A., Jeong, P., Nam, G., Jang, H., Rivera, A., Averette, A. F., Park, E., Liao, T.-C., Ciofani, M., Wu, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2419883121 · Cited by 3
“Inhibition of human CaN suppresses the immune system ( 29 – 31 ).”
The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis
Li, J., Wang, H., Lin, J., Wang, A., Miao, S., & Liu, H. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00008 · Cited by 7
“24 Calcineurin inhibitors selectively bind with high affinity to specific cytoplasmic receptors of immunophilins, such as cyclophilin and FK-binding protein.”
Revolutionizing medicine: Exploring the breakthroughs in liver xenotransplantation
El‐Kassas, M., Abdelhamed, W., & Al-Naamani, K. M. (2025) · Liver Research · doi:10.1016/j.livres.2025.08.001 · Cited by 3
“95 More recently, immunomodulatory drug developments have focused on the identification of targets that control T cell activation and proliferation, such as co-stimulation blockade (e.g., anti-CD154, anti-CD40, and anti-CD28).”
Hori, T., Kuribayashi, K., Saito, K., Wang, L., Torii, M., Üemoto, S., & Kato, T. (2015) · Transplant Immunology · doi:10.1016/j.trim.2015.03.004 · Cited by 3
“Immunosuppressants have revolutionized clinical transplantation, but also cause pan-immunosuppression [12].”
BackgroundWhite-Dzuro, C. G., Pollins, A. C., Kalmar, C. L., Assi, P. E., Rector, J. A., Bellan, L. M., & Thayer, W. P. (2022) · Burns · doi:10.1016/j.burns.2022.02.003 · Cited by 4
Maeng, J., & Lee, K. (2023) · Biochimie · doi:10.1016/j.biochi.2023.03.011 · Cited by 3
Targeting Acute Islet Inflammation to Preserve Graft Mass and Long-Term Function
Darden, C. M., Vasu, S., Kumano, K., Naziruddin, B., & Lawrence, M. C. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1901043 · Cited by 4
Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients
Yoon, E. L. (2019) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2019.74.5.258 · Cited by 3
COVID-19 Treatments for Nonhospitalized Patients
Farmakiotis, D. (2022) · JAMA · doi:10.1001/jama.2022.6167 · Cited by 3
Cyclosporine for Ulcerative Colitis
Botta, G. P., Blonski, W. C., & Lichtenstein, G. R. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1677-1_13 · Cited by 3
“Structural and functional nephrotoxicity is a major concern of patients taking cyclosporine [ 63 ].”
BackgroundZhumatayev, S., Yalçın, K., Çelen, S., Karaman, İ., Daloğlu, H., Öztürkmen, S., Uygun, V., Karasu, G., & Yeşilipek, A. (2024) · Pediatric Transplantation · doi:10.1111/petr.14688 · Cited by 2
“32 In our study, in line with the previous comparable ones, 10–12 nephrotoxicity was more common in the TCR group; however, there was no significant difference in other toxicities.”
ResultImmunosuppression Post-Liver Transplant
Yataco, M. L., & Keaveny, A. P. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.12.006 · Cited by 2
Maurice, N. J., Erickson, J. R., DeJong, C. S., Mair, F., Taber, A. K., Frutoso, M., Islas, L., Vigil, A.-L. B. G., Lawler, R. L., McElrath, M. J., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf093 · Cited by 6
Evans, M. J., Mitchell, T. J., Zaucha, M., Petkau, G., & Turner, M. (2025) · European Journal of Immunology · doi:10.1002/eji.70085 · Cited by 4
“Given that CsA is a potent immunosuppressant [47] and that both ZFP36 and ZFP36L1 have previously been shown to limit T cell-mediated inflammatory and immune responses [13, 14, 17, 18], our observations are relevant to the mechanism of action of CsA as an immunosuppressant.”
Cao, H., Li, X., & Ke, B. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04692-1 · Cited by 2
“On the other hand, as a calcineurin inhibitor, it persistently suppresses T-cell function, thereby indirectly inhibiting the production of pathogenic antibodies [25].”
Unique Considerations When Managing Hypertension in the Transplant Patient
Mitema, D. G., & Schinstock, C. A. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_87 · Cited by 2
“In themodern era of transplantation, calcineurin inhibitors (CNIs) are part of a standard immunosuppressive regimen for most patients (Textor et al. 2000; Hoorn et al. 2012; Azzi et al. 2013).”
BackgroundModulation of calcineurin signaling during development
Edmister, S. T., & Créton, R. (2022) · Developmental Neurobiology · doi:10.1002/dneu.22895 · Cited by 2
“The signaling pathways have been studied extensively in the immune system and calcineurin inhibitors such as cyclosporine A (CsA) and tacrolimus (FK506) are widely used as immunosuppressants in transplant medicine to prevent organ rejection (Azzi et al., 2013).”
BackgroundInfluentialAnti-inflammatory and Antibacterial Activity of the Methanol Extract of Artemisia Herba-Alba.
Zemour, H., Abdelkader, A., Reda, B. A., Abdelkader, B., kheira, B., & lakhdar, Z. (2022) · Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology/Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology · doi:10.21608/eajbsc.2022.296475 · Cited by 3
Liefeldt, L., Waiser, J., Bachmann, F., Budde, K., Friedersdorff, F., Halleck, F., Lachmann, N., Peters, R., Rudolph, B. D., Ünlü, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154305 · Cited by 2
“…(MPA; e.g., mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS)), with or without steroids, has led to major advances in renal transplantation [1] with excellent short-term outcomes, and they are recommended by current guidelines for immunologically low-risk patients [2].”
BackgroundBarzegar‐Fallah, A., Ghaffari‐Bohlouli, P., Nadjafi, S., Razmi, A., Dehpour, A. R., Ghaffarian‐Bahraman, A., Alimoradi, H., & Shafiei, M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177389 · Cited by 2
Gamma Delta T Cells in Solid Organ Transplantation
Bigatti, C., Cocchini, L., Selbach, F., Angeletti, A., & Cravedi, P. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00472-w · Cited by 2
“Calcineurin inhibitors (CNIs) form complexes with intracel - lular immunophilins, which then bind to calcineurin, pre - venting phosphorylation of transcription factors necessary for the activation of T cells [118], including γδ T cells.”
Welzenbach, K., Mancuso, R. V., Krähenbühl, S., & Weitz‐Schmidt, G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13256 · Cited by 2
“CsA is a calcineurin inhibitor modulating TCR-mediated activation of T cells (signal 1), as reviewed recently (Azzi et al., 2013).”
BackgroundSchaiquevich, P. S., Taich, P., Riva, N., Leone, F., Paternoster, N., Mato, G., & Guido, P. (2016) · PubMed · Cited by 2
Idiosyncratic drug reactions and membranous glomerulopathy
Kirpalani, A., Rieder, M. J., Bax, K. C., & Filler, G. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-218496 · Cited by 2
Sato, T., Konno, J., Sekiguchi, A., Yoneki, N., Kawano, K., Hayashi, T., Ogawa, Y., Kikitsu, A., Aijima, T., Hara, K., et al. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0044 · Cited by 2
Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation
Arrabi, L., Jan, A., Hosing, C. M., Milton, D. R., & Yeh, J. C. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13701 · Cited by 2
Mecadon, K., Hardesty, A., Vieira, K., Rogers, R., Merhi, B., Osband, A. J., Bayliss, G. P., Gohh, R., Morrissey, P., & Farmakiotis, D. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221078983 · Cited by 2
“any) and using a modified ordinal scale for worst supplemental oxygen requirement8: (1) invasive mechanical ventilation, died; (2) invasive mechanical ventilation, survived; (3) noninvasive mechanical ventilation; (4) high-flow oxygen device; (5) low-flow oxygen device; and (6) no oxygen requirement.”
BackgroundMethodPharmacokinetic drug-drug interaction study between clindamycin and cyclosporin in rabbits
Abushammala, I. M., El-Gussein, L. A., Zomlot, B. J., Abushammalleh, K. F., Taha, M., & Miqdad, M. Y. (2020) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2020.102016 · Cited by 2
“CSA is widely used as the first line therapy in prophylaxis and treatment of organ transplant rejection (Azzi et al., 2013), rheumatoid arthritis, psoriasis, and other autoimmune diseases (Faulds et al.”
Cardiac Allograft Rejection: Strategies for Success in the Face of Immune Challenges
Patail, H., Khan, S. P., Aggarwal‐Gupta, C., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000596 · Cited by 3
Immunotoxicology: A Brief History
Hastings, K. L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8549-4_1 · Cited by 2
Innovative Trials and New Opportunities in SLE
Chaichian, Y., & Wallace, D. J. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.010 · Cited by 2
Cyclosporin A: Teaching an Old Drug New Tricks?
Noda, K., Bürki, S. E., Kumar, A., & D’Cunha, J. (2019) · Transplantation · doi:10.1097/tp.0000000000002630 · Cited by 2
“Mechanistically, CsA confers the potent immunosuppression effect via inhibition of calcineurin in T cells.(1) Despite decades of experience, this old drug may have new tricks that are underappreciated.”
BackgroundChoy, J. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99563-2 · Cited by 2
Maurice, N. J., Erickson, J. R., DeJong, C. S., Mair, F., Taber, A. K., Frutoso, M., Islas, L., Vigil, A.-L. B. G., Lawler, R. L., McElrath, M. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.10.598377 · Cited by 2
“Though outside the scope of this current study and limited in availability, incorporating tissues from donors on immunosuppressants that limit TCR-mediated activation (76) could provide further granularity regarding the signals that drive residency at the MFI.”
Mycophenolate Mofetil for the Long-Term Treatment of Htlv-1 Associated Myelopathy
Sanz, M., Chernet, S., Shymansky, J., Mandel, A., Chitrakar, A., Kaminski, H. J., Ghosh, P., & Soriano-Sarabia, N. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578294 · Cited by 1
Pharmacogenetics of Tacrolimus in Solid Organ Transplant Patients
Shah, F. A., Ali, A., Bader, Z., & Hassan, G. (2023) · Precision Medicine Communications · doi:10.55627/pmc.003.02.0387 · Cited by 1
Pharmacotherapy of type 1 diabetes – part 3: tomorrow
Rendell, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2468906 · Cited by 1
Goranovič, D., Jenko, B., Ramšak, B., Podgoršek, A., Bedrač, L., Horvat, J., Šala, M., Makuc, D., Carriche, G. M., Silva, L., et al. (2025) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00394 · Cited by 1
Matarneh, A. S., Sardar, S., Akkari, A. M., Mohan, P., Trivedi, N., Kaur, G., & Ghahramani, N. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70351 · Cited by 1
Hassaballa, M. A., Hanna, M. O. F., Radwan, A. M., EL-Adawy, N. M., Helmy, A. K., Fayad, T., El‐Ansary, M., & Saadi, G. E. (2025) · Transplant Immunology · doi:10.1016/j.trim.2025.102268 · Cited by 2
Samuelsson, A., Bayer, A. L., Li, J., Li, Y., Lewis, D., Turcotte, M. G., Dodge‐Kafka, K. L., Alcaide, P., & Kapiloff, M. S. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044692 · Cited by 1
“50 Interestingly, CaN inhibitor-associated nephrotoxicity has been associated with inhibition of renal CaNA α .”
Dieter, R. A., Jaffe, I. S., & Mattoo, A. (2026) · Journal of Pharmacy Practice · doi:10.1177/08971900261427132 · Cited by 1
Kim, G.-T., Shim, S. R., Seo, Y., & Sun, H. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/1982331 · Cited by 1
Langer, P. M., Clare, A. J., Peng, X., Costello, K. L., Cendanawati, S., Wilson, L. L., Ward, A., Bell, O. H., Chu, C. J., Chan, Y., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.018 · Cited by 1
Кучеров, А. А., Ershova, A. I., Novokhatskaya, E. A., Евгеньевич, С. В., & Drapkina, O. M. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2026-4776 · Cited by 2
Original Article Calcineurin inhibitors suppress intestinal cellular respiration
Hammadi, S. A., Souid, A., & Emirates, U. A. (2015) · Cited by 1
Castro-Rojas, C. M., Alloway, R. R., Woodle, E. S., & Hildeman, D. A. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-0225-1 · Cited by 1
Puffy Face and Abdominal Distension
Shashidhara, S., Koushik, H., & Trivedi, S. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-26280-8_22 · Cited by 1
Chang, Y.-C., & Barbas, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-64198-2.00010-5 · Cited by 1
Current Assessment of Clinical Pancreatic Islet Allotransplantation
Chhabra, P., & Brayman, K. L. (2020) · OBM Transplantation · doi:10.21926/obm.transplant.2004125 · Cited by 2
Thoma, M., Langer, K. J., McLean, P., & Dingli, D. (2022) · Transplantation Reports · doi:10.1016/j.tpr.2022.100115 · Cited by 1
Neuropsychiatric Adverse Effects of Immunosuppressant Agents
Cho, S. H., & Crone, C. C. (2022) · Springer eBooks · doi:10.1007/978-3-031-15052-4_35 · Cited by 1
Suresha, A. R., Shashidhar, G., & Prabhudeva, H. (2023) · Kerala Journal of Ophthalmology · doi:10.4103/kjo.kjo_46_22 · Cited by 1
Feng, S., Zhang, T., He, Z., Zhang, W., Chen, Y., Yue, C., & Jing, N. (2024) · Cell Regeneration · doi:10.1186/s13619-024-00191-0 · Cited by 1
“Although many efforts have been made to withdraw CNIs from solid organ transplants to avoid long-term side effects, it has been challenging with significantly high risks of graft rejection (Azzi et al. 2013; Mec-adon 2021).”
BackgroundEl-Awady, S. M. M., Afifi, A. M. E., Afifi, R. M., Sabri, N. A., & Ahmed, M. A. (2024) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-024-00927-y · Cited by 1
“For over three decades, cyclosporin A (CsA) and tacrolimus have been the primary treatment options [13].”
Gadour, E., Miutescu, B. P., Abufarhaneh, E. H., Kuriry, H., Nica, C., Alsheekh, L., Taheri, E., Saeed, Z. A. A., Koppandi, O., Abaalkhail, F. A., et al. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103245 · Cited by 1
Acute Versus Chronic Administration of Calcineurin-Inhibitors Differentially Affect T-Cell Function
Kirchhof, J., Wilde, B., Schmidt, J., Mülling, N., Petrakova, L., Brinkhoff, A., Schedlowski, M., & Witzke, O. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320999200831161710 · Cited by 1
Maintenance Immunosuppression in Kidney Transplantation
Narla, D., Nguyen, C., Mahesh, S., & Raina, R. (2023) · Springer eBooks · doi:10.1007/978-981-19-6909-6_10 · Cited by 1
Immunosuppressive agents and monitoring in long‐term survivors
Culos, K. A. A., & Gatwood, K. S. (2021) · Wiley eBooks · doi:10.1002/9781119612780.ch37 · Cited by 1
Gineste, C., Youhanna, S. C., Vorrink, S. U., Henriksson, S., Hernández, A., Cheng, A. J., Chaillou, T., Buttgereit, A., Schneidereit, D., Friedrich, O., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.29.437546 · Cited by 1
Peng, Q., Wang, G., & Li, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1194649 · Cited by 1
TCR signaling via NFATc1 constrains IL-15-induced NK-like activation of human memory CD8 + T cellsPreprint
Lee, H., Kim, S., Kim, S.-H., Jeong, S., Kim, K. H., Kim, C. G., Koh, J., Kim, H., Han, J. W., Yu, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632884 · Cited by 1
Samuelsson, A., Bayer, A. L., Li, J., Li, Y., Lewis, D., Turcotte, M. G., Dodge‐Kafka, K. L., Alcaide, P., & Kapiloff, M. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653597 · Cited by 1
Transplantation, Immunology, and Cell Biology
Kobayashi, L. M. (2012) · Wiley eBooks · doi:10.1002/9781118274231.ch21
C URRENT OPINION Targeting the immune system to treat hypertension: where are we?
Gooch, J. L., & Sharma, A. C. (2014)
The Inflammatory Environment and Its Effects on Mesenchymal Stem/Stromal Cells
Németh, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803102-5.00018-5
Barrows cards: Therapeutic self-care in a paediatric blood cancer unit
Cambiaso, G., Bagnasco, A., Sasso, L., Ghibaudo, E., Cannavale, F., Olcese, E., D’Ulivo, B., & Morreale, G. (2014) · CINECA IRIS Institutial Research Information System (University of Genoa)
Sadozai, H. (2016) · TSpace (University of Toronto)
Maintenance Immunosuppression in Kidney Transplantation
Cortinovis, M., Remuzzi, G., & Perico, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00020-5
The Immune Response to the Allograft
Carty, F., & English, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00018-7
A Unique Gene Expression Profile to Identify Operationally Tolerant Liver Transplant Recipients
Rojas-Luengas, V. (2016) · TSpace (University of Toronto)
OBSOLETE: Transplant Arteriosclerosis
Choy, J. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99563-1
Hematologic Challenges in Intensive Care Unit Patients with Solid Organ Transplants
Tamayo-Enríquez, G., & Borja–Cacho, D. (2018) · Springer eBooks · doi:10.1007/978-3-319-93572-0_14
Kidney Transplant-Immunosuppression and Rejection
Lockridge, J., & Olyaei, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_4
Opening the Black Box of Immunosuppression
Kaplan, M. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1801320
“Calcineurin inhibitors, a class of immunosuppressant small molecules that includes cyclosporine A (CsA) and FK506, bind to immunophilins (4).”
BackgroundInfluentialNuclear Factor I in Malignant Glioma
Brun, M. M. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3t14v396
Optimizacija zdravljenja s ciklosporinom v Univerzitetnem kliničnem centru Maribor
Stopinšek, M., Drofenik, P., Bevc, S., Roškar, Z., Holc, I., Gorenjak, M., & Mrhar, A. (2020) · Slovenian Medical Journal · doi:10.6016/zdravvestn.2852
Tari, N., Fábián, G., Kaán, M., & Gera, I. (2019) · Fogorvosi Szemle · doi:10.33891/fsz.112.4.123-133
Middle Molecular and Conjugation Strategies for Development of Bioactive Middle Molecules
Manabe, Y., Shimoyama, A., Kabayama, K., & Fukase, K. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.527
Medikamentöse Therapie des Morbus Crohn
Hoffmann, J. (2020) · Springer eBooks · doi:10.1007/978-3-662-59104-8_16
Extracorporeal photopheresis in solid organ transplantation
Kildyushevsky, A. V., Moysyuk, Y. G., Molochkov, A. V., Mitina, T. A., & Faenko, A. P. (2020) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2020-48-046
Graft-Versus-Host Disease (GvHD) Prophylaxis
Pecoraro, J., & Lazarus, H. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_11
Gemcitabine Resistance Elicits a Calcium Dependent Epigenetic Reprogramming in Pancreatic Cancer
Kutschat, A. P. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8475
A therapeutic strategy for Sjögren’s syndrome dry eye
Rolando, M., Roper, N., Figueiredo, F. C., & Aragona, P. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198806684.003.0014
Conjugation Strategies for Development of Bioactive Middle Molecules
Manabe, Y., Shimoyama, A., Kabayama, K., & Fukase, K. (2021) · Springer eBooks · doi:10.1007/978-981-16-2458-2_1
Immunometabolism and Organ Transplantation
Domínguez-Amorocho, O. A., de Lima, J., & Câmara, N. O. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-86684-6_13
Hoi, A. Y.-B. (2021) · Springer eBooks · doi:10.1007/978-3-030-85161-3_8
中村, 祥., & ビートたけし (2006) · 新潮45
Maculopathy and Posterior Reversible Encephalopathy Syndrome Presumably Associated with Tacrolimus
Muñoz, A., Mt, M., Rojas, P., & Carvajal, C. (2022) · Acta Scientific Medical Sciences · doi:10.31080/asms.2022.06.1193
Transplantation, Immunology, and Cell Biology
Kobayashi, L. M., & Cantrell, E. (2018) · Wiley eBooks · doi:10.1002/9781119317913.ch22
DeVreese, L., Tsien, C. D., & Murthy, S. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65640-4
Metadata
- Authors
- Azzi, J. R., Sayegh, M. H., & Mallat, S. G.
- Affiliations
- Brigham and Women's Hospital (US)
- American University of Beirut (LB)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12
- Volume
- 191
- Issue
- 12
- Pages
- 5785-5791
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1592567691
- Cited by
- 337
- References
- 90
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 26 · 2023: 32 · 2022: 44 · 2021: 38 · 2020: 27 · 2019: 27 · 2018: 25 · 2017: 17 · 2016: 25 · 2015: 14 · 2014: 12
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- calcineurin inhibitors, cyclosporine, tacrolimus, organ transplantation, immunosuppression, nephrotoxicity, drug toxicity reduction, autoimmune disease therapy, mechanism of action
- MeSH terms
- Animals, Autoimmune Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Therapy, Combination, Forecasting, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Diseases, Lymphocyte Activation, T-Lymphocytes, Meta-Analysis as Topic, Multicenter Studies as Topic, Kidney Transplantation, Randomized Controlled Trials as Topic, Tacrolimus, Cyclosporine, Calcineurin, History, 20th Century, History, 21st Century, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.